Email Alert | RSS    帮助

中国防痨杂志 ›› 2020, Vol. 42 ›› Issue (2): 173-177.doi: 10.3969/j.issn.1000-6621.2020.02.017

• 综述 • 上一篇    下一篇

结核分枝杆菌对乙硫异烟胺/丙硫异烟胺耐药的机制及其增敏剂研究进展

宋艳华,高孟秋,李琦()   

  1. 101149 首都医科大学附属北京胸科医院结核科(宋艳华、高孟秋),临床中心(李琦)
  • 收稿日期:2019-11-29 出版日期:2020-02-10 发布日期:2020-02-19
  • 通信作者: 李琦 E-mail:lq0703@hotmail.com

Research progress on the mechanism of drug resistance of Mycobacterium tuberculosis to ethionamide/pthionamide and ethionamide boosters

SONG Yan-hua,GAO Meng-qiu,LI Qi()   

  1. Department of Tuberculosis,Beijing Chest Hospital,Capital Medical University, Beijing 101149,China
  • Received:2019-11-29 Online:2020-02-10 Published:2020-02-19
  • Contact: Qi LI E-mail:lq0703@hotmail.com

摘要:

乙硫异烟胺(ethionamide,ETH)/丙硫异烟胺(prothionamide,PTH)是异烟肼(isoniazid,INH)的类似物,属于二线抗结核药品,目前主要用于耐多药结核病(multidrug resistant tuberculosis,MDR-TB)的治疗。ETH/PTH的临床应用受到与INH交叉耐药,以及临床治疗剂量ETH、PTH杀菌作用弱和产生消化道不良反应的影响。最近几年来,基于ETH/PTH的分子作用机制的ETH增敏剂的研究也取得了明显进展。作者复习文献,主要从ETH/PTH耐药及INH交叉耐药机制、增敏剂研究等方面进行了总结。

关键词: 分枝杆菌,结核, 异烟肼, 乙硫异烟胺, 丙硫异烟胺, 结核,抗多种药物性, 药理作用分子作用机制, 综述文献(主题)

Abstract:

Ethionamide (ETH)/prothionamide (PTH) are analogues of isoniazid (INH). They are usually used as second-line anti-tuberculosis drugs on treatment of multidrug resistant tuberculosis(MDR-TB). The clinical usage of ETH/PTH is affected by their cross resistance with INH, weak bactericidal effect and adverse reactions of digestive system they may induce. In recent years, researches of ETH boosters based on molecular mechanism of ETH/PTH have also made significant progress. In this review, the mechanism of ETH/PTH resistance, the mechanism of INH cross resistance and studies of ETH boosters were summarized.

Key words: Mycobacterium tuberculosis, Isoniazid, Ethionamide, Prothionamide, Tuberculosis,multidrug-resistant, Molecular mechanisms of pharmacological action, Review literature (as topic)